New PET scan agent aims to sharply detect multiple cancers

NCT ID NCT07557225

Recruiting now Diagnosis Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The goal is to see how well this scan finds and stages tumors compared to standard imaging, while also checking its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-T2 (a radioactive imaging agent injected intravenously)
What this could lead to: If successful, this could provide a more accurate way to detect and stage certain cancers that express CAIX, potentially improving diagnosis and treatment planning.
What could go wrong: This is an early diagnostic study, not a treatment. The imaging agent may not prove more effective than existing methods, and safety or tolerability issues could arise.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cervical cancer cholangiocarcinoma clear cell renal carcinoma colorectal cancer colorectal neoplasm endometrial cancer endometrium neoplasm head and neck cancer Head and Neck Neoplasms hepatocellular carcinoma malignant pancreatic neoplasm non-small cell lung carcinoma ovarian cancer pancreatic neoplasm renal cell carcinoma small cell lung carcinoma transitional cell carcinoma urothelial carcinoma Uterine Cervical Neoplasms von Hippel-Lindau disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER CERVICAL CANCER CHOLANGIOCARCINOMA CLEAR CELL RENAL CELL CANCER (CCRCC) COLORECTAL CANCER ENDOMETRIAL CANCER HEAD AND NECK CANCER HEPATOCELLULAR CARCINOMA (HCC) NON-SMALL CELL LUNG CANCER OVARIAN CANCER PANCREATIC CANCER SMALL CELL LUNG CANCER UROTHELIAL CARCINOMA (UC) VON HIPPEL-LINDAU DISEASE

Contacts and locations

Locations

Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.